Ignite Creation Date:
2024-05-06 @ 3:38 AM
Last Modification Date:
2024-10-26 @ 11:36 AM
Study NCT ID:
NCT02333760
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2021-06-03
First Post:
2014-10-28
Brief Title:
Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome
Sponsor:
Genethon
Organization:
Genethon
Study Overview
Official Title:
Long Term Safety Follow up of Patients Enrolled in the Phase III Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome GTG002-07 and GTG003-08
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
WASFUP
Brief Summary:
An open follow up study of patients enrolled in the Phase 12 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome and treated with autologous CD34 cells transduced with the w16_hWASP_WPRE VSVg lentiviral vector
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None